Investigational drug · Phase 2
COM701
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Ovarian Cancer, Ovarian Cancer Recurrent.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 6, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
4
Any phase or sponsor naming "COM701"
First trial start
2025
Jul 21, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "COM701", any sponsor or status.
Conditions studied
As listed on its trial records.
- Ovarian Cancer
- Ovarian Cancer Recurrent
Approved drugs for the same conditions: Ovarian cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "COM701" as an intervention, largest first.
Compugen LtdIndustry
NCT03667716 · 121 participants · Start Sep 6, 2018 · Primary completion Jan 30, 2024
Drug: COM701; COM701 with Opdivo (Nivolumab). · For: Advanced Cancer; Ovarian Cancer; Breast Cancer and 7 more
Sites: Los Angeles, California; Sarasota, Florida; Chicago, Illinois · 11 sites in all
Compugen LtdIndustry
NCT04354246 · 94 participants · Start Mar 31, 2020 · Primary completion Apr 1, 2026
Drug: Dose escalation: COM902 monotherapy.; Cohort expansion: COM902 (RDFE) monotherapy. and 1 more · For: Advanced Cancer; Ovarian Cancer; Lung Cancer and 6 more
Sites: Sarasota, Florida; Boston, Massachusetts; Grand Rapids, Michigan · 9 sites in all
- A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian CancerActive, not recruiting
Compugen LtdIndustry
NCT06888921 · 60 participants (planned) · Start Jul 21, 2025 · Primary completion Mar 2027
Drug: COM701; Normal Saline · For: Ovarian Cancer; Ovarian Cancer Recurrent
Sites: Augusta, Georgia; Chicago, Illinois; Warrenville, Illinois · 27 sites in all
- COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors.Completed
Compugen LtdIndustry
NCT04570839 · 48 participants · Start Aug 31, 2020 · Primary completion May 15, 2024
Drug: COM701 in combination with BMS-986207 and nivolumab. · For: Endometrial Neoplasms; Ovarian Cancer; Solid Tumor and 1 more
Sites: Chicago, Illinois; Baltimore, Maryland; Boston, Massachusetts · 9 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- COM902, a novel therapeutic antibody targeting TIGIT augments anti-tumor T cell function in combination with PVRIG or PD-1 pathway blockade.
Hansen K, Kumar S, Logronio K, et al. · Cancer Immunol Immunother 2021
- COM701 Shows Antitumor Activity, +/- Nivolumab.
· Cancer Discov 2020
Also in development for Ovarian Cancer
- SHR-A1811Trastuzumab RezetecanPhase 327 trials
Jiangsu HengRui Medicine Co., Ltd. · Advanced Colorectal Cancer, Recurrent or Metastatic Cervical Cancer, Ovarian Cancer
- RilvegostomigAZD2936Phase 325 trials
AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- GiredestrantRO7197597, GDC-9545Phase 316 trials
Roche (Genentech) · Early Breast Cancer, Breast Cancer, Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer
- SG001enlonstobart, Enlonstobart will be administrated on a 14-day cyclePhase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · HER2-positive Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- FianlimabREGN3767Phase 311 trials
Regeneron · Melanoma, Non-small Cell Lung Cancer, Hepatocellular Carcinoma
- LBL-024Phase 311 trials
Nanjing Leads Biolabs Co.,Ltd · Advanced Solid Tumour, Advanced Extrapulmonary Neuroendocrine Carcinoma, Metastatic Colorectal Carcinoma
- R-DXdDS 6000a, MK-5909Phase 310 trials
Merck & Co. · Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cancer
- SaruparibAZD5305Phase 310 trials
AstraZeneca · Prostate Cancer, Ovarian Cancer, Endometrial Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.